



**SDI Review Form 1.6**

Journal Name:	<a href="#">International Blood Research &amp; Reviews</a>
Manuscript Number:	Ms_IBRR_48732
Title of the Manuscript:	Relationship among HbA1c and some Markers of Endothelial Damage in type 2 Diabetes Mellitus
Type of the Article	Original Research Article

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



**SDI Review Form 1.6**

**PART 1: Review Comments**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<ul style="list-style-type: none"> <li>Abbreviations appearing first time in main text must have expanded version followed by abbreviation within brackets: 'the major physiological inhibitor of tPA' – change it as: 'tissue plasminogen activator (tPA).'</li> <li>Key words must be 5-10 in number in MeSH terms other than those found in title in alphabetical order.</li> <li>References are not up to date.</li> <li>References list also should be numbered in square brackets as in main text citations.</li> <li>The references should be in Vancouver style. For full details on this refer to the following link to university of Queensland (<a href="http://www.library.uq.edu.au/training/citation/vancouv.pdf">http://www.library.uq.edu.au/training/citation/vancouv.pdf</a>)</li> <li>The titles of journals should be in italics and abbreviated according to the style used in Index Medicus/ NLM Catalog.</li> <li>Sample size is small and number of patients. in the study group and in the control group is not statistically equal (30 in study group and 25 in control group. It could have been made 30 and 30). Atleast this could have been mentioned as limitations of study with reasoning.</li> <li>It is mentioned as 'apparently healthy persons in the conrol group', what does it mean? Either symptomatically healthy or T2DM ruled out with investigation? It has to be clarified.</li> </ul>	<p>tissue plasminogen activator (tPA)</p> <p><i>endothelial, glycated, haemoglobin,</i></p> <p>some of the references were up dated</p> <ol style="list-style-type: none"> <li>Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP. Endothelial Dysfunction in Diabetes. Diabetes Care. 2011;34(Supplement 2):S285–S290.</li> <li>Syrovets T, Lunov O, Simmet T. Plasmin as a proinflammatory cell activator. J. Leukoc. Biol. 2012;92:509–519.</li> <li>Gavriilaki E, Gkaliagkousi E, Nikolaidou B, Triantafyllou G, Chatzopoulou F, Douma S. Increased thrombotic and impaired fibrinolytic response to acute exercise in patients with essential hypertension: the effect of treatment with an angiotensin II receptor blocker. Journal of Human Hypertension. 2014;28:606–609.</li> <li>Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. American Journal of Gastroenterology. 2011;106:713–718.</li> </ol> <p>Limitations of the study were mentioned</p> <p>Non diabetic</p>
<b>Minor</b> REVISION comments		
<b>Optional/General</b> comments	<p>Well done study.</p> <p>Corrections and suggesions mentioned above have to be caried out by the authors.</p>	

**PART 2:**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	